Molecular Pharmaceutics
[ASAP] Linear Peptide-Based PET Tracers for Imaging PD-L1 in Tumors
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.3c00382
Molecular Pharmaceutics
[ASAP] Relaxin-Loaded Inhaled Porous Microspheres Inhibit Idiopathic Pulmonary Fibrosis and Improve Pulmonary Function Post-Bleomycin Challenges
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.3c00111
Molecular Pharmaceutics
[ASAP] Understanding the Effect of Nucleation in Amorphous Solid Dispersions through Time–Temperature Transformation
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.3c00313
Molecular Pharmaceutics
[ASAP] LNP-miR-155 cy5 Inhibitor Regulates the Copper Transporter via the β‑Catenin/TCF4/SLC31A1 Signal for Colorectal Cancer Therapy
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.3c00276
Molecular Pharmaceutics
[ASAP] Control of Dissolution and Supersaturation/Precipitation of Poorly Water-Soluble Drugs from Cocrystals Based on Solubility Products: A Case Study with a Ketoconazole Cocrystal
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.3c00237
Molecular Pharmaceutics
[ASAP] Distribution of Female and Male First and Last Authorship across Drug Delivery Related Journals with Respect to Year and Journal Impact Factor
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.3c00328
Molecular Pharmaceutics
[ASAP] Biomimetic Nanoparticles Loaded with Ulinastatin for the Targeted Treatment of Acute Pancreatitis
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.3c00238
Molecular Pharmaceutics
[ASAP] Construction of SLC16A1/3 Targeted Gallic Acid-Iron-Embelin Nanoparticles for Regulating Glycolysis and Redox Pathways in Cervical Cancer
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.3c00294
Molecular Pharmaceutics
[ASAP] Molecular Dynamics Simulation Studies of Bile, Bile Salts, Lipid-Based Drug Formulations, and mRNA–Lipid Nanoparticles: A Review
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.3c00049
Molecular Pharmaceutics
[ASAP] Antifibrotic Agent Mediated Tumor Microenvironment Modulation and Improved Nanomedicine Delivery in Solid Tumor
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c01081